Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs Synopsys, Inc. (SNPS) Price & Performance

Citius Pharmaceuticals IncTrade
Synopsys, Inc.Trade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs Synopsys, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.76 (market cap $20.01M), while Synopsys, Inc. trades at $413.65 (market cap $78.68B). The key difference: Synopsys, Inc. is far larger — about 3932× Citius Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.

CTXRSNPS
Market Cap
$20.01M$78.68B
Sector
HealthTechnology
52-Week High
$1.82$625.80
52-Week Low
$0.48$372.33
Enterprise Value
$16.23M$87.04B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.

The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.

Synopsys, Inc.

Synopsys (SNPS) trades at $413.78, up 0.51% on the day, with a bearish technical signal despite recent earnings beats. The stock shows high valuation ratios (P/E of 94.03, P/S of 8.68) but maintains strong gross margins of 73.47%. Recent news highlights AI-driven growth from the Ansys acquisition and partnerships with AMD and Microsoft, though cash flow trends show volatility with a net outflow of $1.01B in 2025.

Outlook remains positive with analyst consensus favoring Buy (82.76%) and a $551 price target, but risks include elevated valuation, competitive pressures, and integration challenges from acquisitions. Earnings growth and AI adoption in chip design are key catalysts, yet investors should monitor margin sustainability and debt levels amid expansion.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About Synopsys, Inc.

Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.

Read more on SNPS